Image

Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses

Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses

Non Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

ctDNA detection in patients with previously treated, HPV-induced, stage II or III invasive pelvic cancer and who are currently in post-treatment follow-up.

Description

Patients with previously treated, HPV-induced, stage II or III invasive pelvic cancer and who are currently in post-treatment follow-up will be included.

These patients will be followed up during 30 months (2.5 years) (if no relapse occurred before) with ctDNA detection performed at each hospital visit. At each visit, clinical, biological (squamous cell carcinoma (SCC) serum marker will be done systematically) and radiological/pathology (if any) results will be prospectively collected in the study.

For the patients who have a relapse or new HPV-induced invasive cancer before 30 months, the follow-up will be discontinued at the date of the relapse.

For the patients who will have completed their follow-up for the study (2.5 years) with no relapse or new HPV-induced invasive cancer, they will be followed up for 6 months (+ 14 days), to collect any late relapse (if any). None specific study procedure will be performed during this period.

Eligibility

Inclusion Criteria:

  1. 1) Patient curatively treated within the past 3 years for:
    • a HPV-induced stage Ib3, Ic, II or III cervix cancer
    • a HPV-induced stage II or III anal canal, vagina, vulva or penis cancer
  2. Patient with no evidence of any invasive tumor at inclusion (clinical and, if any,

    radiological exams).

  3. Age ≥ 18 years
  4. Availability of HPV genotyping of the treated cancer and/or archived tumor tissue available.
  5. Patient who a follow-up visit is scheduled in the including center at least twice a year.
  6. Patient being affiliated to the French social security.
  7. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  1. Patient presenting with active invasive tumor masses (e.g. stage IV cancer).
  2. Patient deprived from ability to decide on her own or placed under the authority of a tutor.
  3. Patient unable to have a regular follow up for geographical, social or psychological reasons.

Study details
    HPV Positive Pelvic Cancer

NCT03739775

Institut Curie

21 October 2025

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.